XCancer

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Description:

This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared. Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.

Sponsor:

Unknown Organization

Phase:

Phase 2

Contacts:

Tony Lahoutte, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03331601 - Click here to see study on

ClinicalTrials.gov

NOTA-Anti-HER2 VHH1

Isotope(s):
Target(s):
  • HER2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA
Inclusion
  • Patients with brain metastasized cancer, with at least 1 brain lesion of at least 8 mm maximal diameter, as measured by CT or MRI.
  • * Patients who have given informed consent
  • Age 18 years or older
  • Patients with potentially HER2-positive cancer. Either a HER2 staining should have been done in standard of care, or sufficient tissue should be available for HER2-staining for study purpose.
Exclusion
  • Patients with any serious active infection
  • Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the test radiopharmaceutical
  • Patients with recent (\< 1 week) gastrointestinal disorders with diarrhea as major symptom
  • Breast feeding patients
  • * Pregnant patients